Impact of liposomal bupivacaine on opioid use, hospital length of stay, discharge status, and hospitalization costs in patients undergoing total hip arthroplasty

References

• Barbour KE, Helmick CG, Boring M, et al. Vital signs: prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation - United States, 2013–2015. MMWR Morb Mortal Wkly Rep. 2017;66:246–253.
   PubMed Web of Science ®Google Scholar
• Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007;89:780–785.
   PubMed Web of Science ®Google Scholar
• Kurtz SM, Lau E, Ong K, et al. Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030. Clin Orthop Relat Res. 2009;467:2606–2612.
   PubMed Web of Science ®Google Scholar
• Nwachukwu BU, Bozic KJ, Schairer WW, et al. Current status of cost utility analyses in total joint arthroplasty: a systematic review. Clin Orthop Relat Res. 2015;473:1815–1827.
   PubMed Web of Science ®Google Scholar
• Nwachukwu BU, McCormick F, Provencher MT, et al. A comprehensive analysis of Medicare trends in utilization and hospital economics for total knee and hip arthroplasty from 2005 to 2011. J Arthroplasty. 2015;30:15–18.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. 2019. Comprehensive care for joint replacement model. [cited 2018 June 21]. Available from: https://innovation.cms.gov/initiatives/cjr
   Google Scholar
• Chen KK, Harty JH, Bosco JA. It is a brave new world: alternative payment models and value creation in total joint arthroplasty. J Arthroplasty. 2017;32:1717–1719.
   PubMed Web of Science ®Google Scholar
• Nichols CI, Vose JG. Clinical outcomes and costs within 90 days of primary or revision total joint arthroplasty. J Arthroplasty. 2016;31:1400–1406. e1403.
   PubMed Web of Science ®Google Scholar
• Molloy IB, Martin BI, Moschetti WE, et al. Effects of the length of stay on the cost of total knee and total hip arthroplasty from 2002 to 2013. J Bone Joint Surg Am. 2017;99:402–407.
   PubMed Web of Science ®Google Scholar
• Ramkumar PN, Chu CT, Harris JD, et al. Causes and rates of unplanned readmissions after elective primary total joint arthroplasty: a systematic review and meta-analysis. Am J Orthop (Belle Mead NJ). 2015;44:397–405.
   PubMedGoogle Scholar
• Clement RC, Derman PB, Graham DS, et al. Risk factors, causes, and the economic implications of unplanned readmissions following total hip arthroplasty. J Arthroplasty. 2013;28:7–10.
   PubMed Web of Science ®Google Scholar
• Scuderi GR. The challenges of perioperative pain management in total joint arthroplasty. Am J Orthop (Belle Mead NJ). 2015;44:S2–S4.
   PubMedGoogle Scholar
• Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17:131–157.
   PubMed Web of Science ®Google Scholar
• Grant CRK, Checketts MR. Analgesia for primary hip and knee arthroplasty: the role of regional anaesthesia. Cont Ed Anaesth Crit Care Pain. 2008;8:56–61.
   Google Scholar
• Minkowitz HS, Gruschkus SK, Shah M, et al. Adverse drug events among patients receiving postsurgical opioids in a large health system: risk factors and outcomes. Am J Health Syst Pharm. 2014;71:1556–1565.
   PubMed Web of Science ®Google Scholar
• Oderda GM, Gan TJ, Johnson BH, et al. Effect of opioid-related adverse events on outcomes in selected surgical patients. J Pain Palliat Care Pharmacother. 2013;27:62–70.
   PubMedGoogle Scholar
• Ilfeld BM. Continuous peripheral nerve blocks: an update of the published evidence and comparison with novel, alternative analgesic modalities. Anesth Analg. 2017;124:308–335.
   PubMed Web of Science ®Google Scholar
• Halawi MJ, Vovos TJ, Green CL, et al. Opioid-based analgesia: impact on total joint arthroplasty. J Arthroplasty. 2015;30:2360–2363.
   PubMed Web of Science ®Google Scholar
• Kessler ER, Shah M, Gruschkus SK, et al. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013;33:383–391.
   PubMed Web of Science ®Google Scholar
• EXPAREL® (bupivacaine liposome injectable suspension). Full Prescribing Information, Pacira Pharmaceuticals, Inc., San Diego, CA, 2018.
   Google Scholar
• Joshi GP, Cushner FD, Barrington JW, et al. Techniques for periarticular infiltration with liposomal bupivacaine for the management of pain after hip and knee arthroplasty: a consensus recommendation. J Surg Orthop Adv. 2015;24:27–35.
   PubMedGoogle Scholar
• Hu D, Onel E, Singla N, et al. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig. 2013;33:109–115.
   PubMed Web of Science ®Google Scholar
• Barrington JW, Olugbode O, Lovald S, et al. Liposomal bupivacaine: a comparative study of more than 1000 total joint arthroplasty cases. Orthop Clin North Am. 2015;46:469–477.
   PubMed Web of Science ®Google Scholar
• Asche CV, Ren J, Kim M, et al. Local infiltration for postsurgical analgesia following total hip arthroplasty: a comparison of liposomal bupivacaine to traditional bupivacaine. Curr Med Res Opin. 2017;33:1283–1290.
   PubMed Web of Science ®Google Scholar
• Yu SW, Szulc AL, Walton SL, et al. Liposomal bupivacaine as an adjunct to postoperative pain control in total hip arthroplasty. J Arthroplasty. 2016;31:1510–1515.
   PubMed Web of Science ®Google Scholar
• Emerson RH, Barrington JW, Olugbode O, et al. Comparison of local infiltration analgesia to bupivacaine wound infiltration as part of a multimodal pain program in total hip replacement. J Surg Orthop Adv. 2015;24:235–241.
   PubMedGoogle Scholar
• Cherian JJ, Barrington J, Elmallah RK, et al. Liposomal bupivacaine suspension can reduce length of stay and improve discharge status of patients undergoing total hip arthroplasty. Surg Technol Int. 2015;27:235–239.
   PubMedGoogle Scholar
• McGraw-Tatum MA, Groover MT, George NE, et al. A prospective, randomized trial comparing liposomal bupivacaine vs fascia iliaca compartment block for postoperative pain control in total hip arthroplasty. J Arthroplasty. 2017;32:2181–2185.
   PubMedGoogle Scholar
• Howell DC, Rogier M, Yzerbyt V, et al. Statistical Methods in Human Sciences. New York: Wadsworth; 1998.
   Google Scholar
• Lovald ST, Ong KL, Malkani AL, et al. Complications, mortality, and costs for outpatient and short-stay total knee arthroplasty patients in comparison to standard-stay patients. J Arthroplasty. 2014;29:510–515.
   PubMed Web of Science ®Google Scholar
• Domb BG, Gupta A, Hammarstedt JE, et al. The effect of liposomal bupivacaine injection during total hip arthroplasty: a controlled cohort study. BMC Musculoskelet Disord. 2014;15:310.
   PubMed Web of Science ®Google Scholar
• Mont MA, Beaver WB, Dysart SH, et al. Local infiltration analgesia with liposomal bupivacaine improves pain scores and reduces opioid use after total knee arthroplasty: results of a randomized controlled trial. J Arthroplasty. 2018;33:90–96.
   PubMed Web of Science ®Google Scholar
• Frieden TR. Evidence for health decision making - beyond 1randomized, controlled trials. N Engl J Med. 2017;377:465–475.
   PubMed Web of Science ®Google Scholar